Compare Johnson & Johnson (JNJ) vs Tenaris S.A. American Depositary Shares (TS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Tenaris S.A. American Depositary Shares — how do they compare? Johnson & Johnson trades at $258.17 (market cap $599.12B), while Tenaris S.A. American Depositary Shares trades at $57.8 (market cap $29.31B). The key difference: Johnson & Johnson is far larger — about 20.4× Tenaris S.A. American Depositary Shares's market cap, and Tenaris S.A. American Depositary Shares pays the higher dividend (4.07%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Tenaris S.A. American Depositary Shares for 0 Days on average.
| JNJ | TS | |
|---|---|---|
Market Cap | $599.12B | $29.31B |
Volume | 16,640,951 | 802,043 |
Sector | Health | Energy |
52-Week High | $278.43 | $64.02 |
52-Week Low | $186.00 | $34.28 |
Typical Hold Time | 129 Days | 0 Days |
Enterprise Value | $627.40B | $26.97B |
Dividend Yield | 2.16% | 4.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JNJ trades at $253.91, down 3.72% on the day, amid a mixed technical and fundamental backdrop. The stock shows strong profitability with a 21.48% net income margin and 25.74% ROE, supported by three consecutive quarterly EPS beats. Analyst consensus is bullish with a $282.73 price target, though recent news highlights competitive pressures and patent cliff concerns. Cash flow trends indicate robust operations but elevated investing outflows.
The outlook remains positive given JNJ's diversified healthcare portfolio and innovation pipeline, but investors face risks from debt levels rising to 24.06% of assets and biosimilar competition. Near-term resistance lies at $265, with support at $257. Institutional sentiment favors growth in pharmaceuticals and medical technology, though macroeconomic and regulatory headwinds persist.
Tenaris (TS) trades at $58.54, up 0.84% with neutral technical signals and strong fundamental metrics including a P/E of 15.65 and net income margin of 15.88%. Recent earnings beats and a $1.18 dividend support investor confidence, though cash flow trends show modest net outflows. The stock faces near-term headwinds from shipment delays and margin compression as noted in recent analyst reports.
The outlook remains balanced with analyst consensus favoring Buy (57.69%) and a $66.67 price target suggesting 14% upside. Key risks include cyclical energy sector exposure and operational disruptions, but solid profitability and valuation support make TS attractive for dividend and value investors seeking energy sector exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Tenaris S.A. American Depositary Shares
Tenaris S.A. manufactures seamless and welded steel pipe products, including casing, tubing, and line pipe, for the oil and gas industry and certain industrial applications. The company operates an integrated production network across 17 countries and offers Rig Direct, its integrated supply-chain service for oilfield customers.
Read more on TS →
